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BSTRACT
 
Background
 
It is unknown whether either the an-
giotensin-II–receptor blocker irbesartan or the cal-
cium-channel blocker amlodipine slows the progres-
sion of nephropathy in patients with type 2 diabetes
independently of its capacity to lower the systemic
blood pressure.
 
Methods
 
We randomly assigned 1715 hypertensive
patients with nephropathy due to type 2 diabetes to
treatment with irbesartan (300 mg daily), amlodipine
(10 mg daily), or placebo. The target blood pressure
was 135/85 mm Hg or less in all groups. We compared
the groups with regard to the time to the primary
composite end point of a doubling of the base-line se-
rum creatinine concentration, the development of end-
stage renal disease, or death from any cause. We also
compared them with regard to the time to a second-
ary, cardiovascular composite end point.
 
Results
 
The mean duration of follow-up was 2.6
years. Treatment with irbesartan was associated with
a risk of the primary composite end point that was 20
percent lower than that in the placebo group (P=0.02)
and 23 percent lower than that in the amlodipine
group (P=0.006). The risk of a doubling of the serum
creatinine concentration was 33 percent lower in the
irbesartan group than in the placebo group (P=0.003)
and 37 percent lower in the irbesartan group than in
the amlodipine group (P<0.001). Treatment with irbe-
sartan was associated with a relative risk of end-stage
renal disease that was 23 percent lower than that in
both other groups (P=0.07 for both comparisons).
These differences were not explained by differences
in the blood pressures that were achieved. The serum
creatinine concentration increased 24 percent more
slowly in the irbesartan group than in the placebo
group (P=0.008) and 21 percent more slowly than in
the amlodipine group (P=0.02). There were no signif-
icant differences in the rates of death from any cause
or in the cardiovascular composite end point.
 
Conclusions
 
The angiotensin-II–receptor blocker
irbesartan is effective in protecting against the pro-
gression of nephropathy due to type 2 diabetes. This
protection is independent of the reduction in blood
pressure it causes. (N Engl J Med 2001;345:851-60.)
 
Copyright © 2001 Massachusetts Medical Society.
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IABETES mellitus is increasing in preva-
lence worldwide and is currently estimat-
ed to affect more than 6.5 percent of the
population of the United States.
 
1
 
 Diabetes
is the most common cause of end-stage renal disease
in this country, accounting for 40 percent of cases.
 
2
 
Although the inhibition of the effects of angiotensin
II has a beneficial effect in patients with nephropathy
caused by type 1 diabetes,
 
3
 
 no published study with
definitive renal outcomes has addressed the issue of
renoprotection in patients with type 2 diabetes — a
population that differs substantially from patients with
type 1 diabetes in terms of demographic characteris-
tics, metabolic features, and potential mechanisms of
glomerular disease.
 
4
 
 Several studies have addressed
the positive effects of specific antihypertensive agents
on cardiovascular morbidity and mortality within this
population.
 
5-8
 
We undertook the Irbesartan Diabetic Nephropathy
Trial to determine whether the use of an angioten-
sin-II–receptor blocker or a calcium-channel blocker
would provide protection against the progression of
nephropathy due to type 2 diabetes beyond that at-
tributable to the lowering of the blood pressure. We
also compared the groups assigned to different ther-
apeutic regimens in terms of overall mortality and the
rate of cardiovascular events.
D
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METHODS
 
We conducted a prospective, randomized, double-blind clinical
trial in 210 clinical centers. The conduct of the study was man-
aged and monitored by the clinical coordinating center and the var-
ious committees of the Collaborative Study Group. All decisions
regarding the biostatistical protocol, study plans, and analyses, in-
cluding the data presented to the data safety and monitoring board,
were the product of the biostatistical coordinating center of the
study group. The biostatistics and data management department
of Bristol-Myers Squibb was responsible for data handling, in-
cluding entry into the master data base, data-base review, and au-
dit. The blinded clinical data base was provided to the biostatis-
tical coordinating center of the Collaborative Study Group for
the generation of interim reports and for final statistical analyses
for publications. Details of the protocol have been published previ-
ously.
 
9
 
 The institutional review board or ethics committee of each
center approved the protocol, and all patients gave written informed
consent after reviewing a written summary of the study plan.
 
Study Patients
 
The criteria for eligibility included an age between 30 and 70
years, a documented diagnosis of type 2 diabetes mellitus, hyperten-
sion (a systolic blood pressure of more than 135 mm Hg while
sitting, a diastolic blood pressure of more than 85 mm Hg while sit-
ting, or documented treatment with antihypertensive agents), and
proteinuria, with urinary protein excretion of at least 900 mg per
24 hours. The serum creatinine concentration was required to be
between 1.0 and 3.0 mg per deciliter (88 and 265 µmol per liter)
in women and 1.2 and 3.0 mg per deciliter (106 and 265 µmol per
liter) in men.
 
Randomization and Treatment Plan
 
All angiotensin-converting–enzyme (ACE) inhibitors, angio-
tensin-receptor blockers, and calcium-channel blockers were discon-
tinued at least 10 days before the screening period, during which
time blood pressure was controlled with other agents. Eligible pa-
tients were randomly assigned by a central office to one of three
treatment regimens: irbesartan (Avapro, Bristol-Myers Squibb,
Princeton, N.J.), in a dose titrated from 75 to 300 mg per day;
amlodipine (Norvasc, Pfizer, New York), in a dose titrated from
2.5 to 10 mg per day; or placebo. Antihypertensive agents other
than ACE inhibitors, angiotensin-receptor blockers, and calcium-
channel blockers were used as needed in each group, and the tar-
get blood pressure for all patients was the same (a systolic blood
pressure of 135 mm Hg or less, or 10 mm Hg lower than the val-
ue at screening if that value was more than 145 mm Hg, and a
diastolic blood pressure of 85 mm Hg or less). Survival, end-stage
renal disease, the cardiovascular end points, the serum creatinine
and potassium concentrations, and the 24-hour urinary protein
excretion were monitored quarterly. Blood-pressure measurements
were reviewed by a clinical management committee that made
treatment recommendations. The committee also monitored blood
glucose concentrations by measurement of glycosylated hemoglo-
bin. Adherence to the treatment regimen was monitored by means
of pill counts. Serum creatinine concentrations were determined
by a central laboratory. Serum potassium and urinary protein were
measured in four regional laboratories. A protocol was established
for the management of hyperkalemia and the detection of early
increases in the creatinine concentration that might be caused by
renal-artery stenosis.
 
9
 
 We planned to continue recruitment for three
years and to follow all patients for a minimum of two years after the
end of recruitment; data were censored on December 31, 2000.
The mean arterial blood pressure was calculated as the diastolic
blood pressure plus one third of the difference between the systolic
blood pressure and the diastolic blood pressure. Values for urinary
protein excretion were log-transformed to reduce skewness.
 
End Points
 
The primary end point was the composite of a doubling of the
base-line serum creatinine concentration, the onset of end-stage
renal disease (as indicated by the initiation of dialysis, renal trans-
plantation, or a serum creatinine concentration of at least 6.0 mg
per deciliter [530 µmol per liter]), or death from any cause. The sec-
ondary, cardiovascular end point was the composite of death from
cardiovascular causes, nonfatal myocardial infarction, heart failure
resulting in hospitalization, a permanent neurologic deficit caused
by a cerebrovascular event, or lower limb amputation above the an-
kle. The serum creatinine outcomes were confirmed with the use
of centrally determined concentrations of serum creatinine. All out-
comes were reviewed and classified by an outcome committee.
Adverse events were recorded at quarterly visits.
 
Statistical Analysis
 
Comparisons of base-line values and outcomes that were not
time dependent among the three treatment groups were made with
the chi-square test (for categorical data) or analysis of variance (for
continuous data). The times to the primary end point and its com-
ponents were compared by means of product-limit survival curves
and the log-rank test.
 
10
 
 All analyses were based on the intention-
to-treat principle. Comparisons of the survival curves for the sec-
ondary, cardiovascular end point were made by means of the
Breslow–Gehan test.
 
11
 
 Adjustment for base-line covariates was per-
formed with the use of Cox proportional-hazards models with
terms for the treatment assignment and the base-line covariates.
 
12
 
Similar proportional-hazards models were used to adjust for time-
dependent covariates such as the mean arterial pressure. In calcu-
lating the slopes of the rates of change of the serum creatinine
concentration and creatinine clearance, a mixed model was used in
which the data for patients who reached an end point were cen-
sored. Comparisons among subgroups defined according to the fre-
quency of serious adverse events were performed with the use of
methods for comparing Poisson counts.
 
13
 
 All statistical tests were
two-sided.
On the basis of the results of our study of type 1 diabetes,
 
3
 
 in
which the three-year rate of a doubling of the base-line serum cre-
atinine concentration, end-stage renal disease, or death was 36 per-
cent, we estimated that we would need 550 patients per treatment
group for an analysis of the primary outcome. The sample size was
selected to achieve 90 percent power to detect a 26 percent dif-
ference in the primary end point between the irbesartan group
and the placebo group at a 5 percent alpha level.
An independent data and safety monitoring board monitored
the study. The Lan–DeMets alpha spending-function method
 
13
 
was used to adjust for interim analyses. Four formal interim analy-
ses were performed. The adjusted level of significance for the final
analysis of the primary outcome was P=0.04.
For all other outcomes, a P value of 0.05 or less was considered
to indicate significance. The protocol defined the comparison of
the irbesartan group with the placebo group as the primary com-
parison and the comparison of the irbesartan group with the am-
lodipine group as the secondary comparison. Because the protocol
identified one primary comparison, the reported P values were
not corrected for multiple comparisons.
 
RESULTS
 
Between March 21, 1996, and February 25, 1999,
1715 patients underwent randomization. The base-
line demographic, clinical, and laboratory character-
istics of the three groups were similar (Table 1), ex-
cept that a slightly lower proportion of the patients
in the placebo group were female (P=0.02). The out-
comes for these patients are summarized in Table 2.
 
Clinical Management
 
The blood-pressure measurements for the three
groups are shown in Figure 1. In all three groups, the
proportion of patients in whom the target blood
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pressure was achieved increased and the mean blood
pressure decreased over the course of the study; the
mean blood pressure at visits after base line was 140/
77 mm Hg in the irbesartan group, 141/77 mm Hg
in the amlodipine group, and 144/80 mm Hg in the
placebo group. The mean arterial pressure was signif-
icantly higher (by 3.3 mm Hg) in the placebo group
than in the two active-treatment groups (P=0.001 for
both comparisons), between which it did not differ
significantly. The distribution of classes of nonstudy
drugs used to control blood pressure — primarily di-
uretics, beta-blockers, peripheral alpha-blockers, and
central 
 
a
 
2
 
 agonists — was similar in all groups. The
patients in the placebo group required an average of
3.3 nonstudy drugs for the control of blood pressure,
as compared with an average of 3.0 nonstudy drugs
among the patients in the irbesartan and amlodipine
groups. The mean glycosylated hemoglobin values did
not differ significantly among the treatment groups or
vary significantly over time.
 
Primary, Renal Outcome
 
The proportions of patients in each group who
reached the primary end point are shown in Figure
2A. The patients in the irbesartan group had an un-
adjusted relative risk of reaching the primary end
point that was 20 percent lower than that in the pla-
cebo group (P=0.02) and 23 percent lower than that
in the amlodipine group (P=0.006) (Table 3). The
relative risk of the primary end point in the placebo
and amlodipine groups did not differ significantly. The
proportions of patients in each group who reached
each of the three components of the primary end
point are shown in Figures 2B, 2C, and 2D. Among
the patients assigned to irbesartan, the unadjusted
relative risk of a doubling of the serum creatinine con-
centration was 33 percent lower than that among the
patients assigned to placebo (P=0.003) (Table 3)
and 37 percent lower than that among the patients
assigned to amlodipine (P<0.001). The unadjusted
relative risk of end-stage renal disease (P=0.07) was
23 percent lower in the irbesartan group than in ei-
ther the amlodipine group or the placebo group (Ta-
ble 3). The placebo and amlodipine groups did not
differ significantly with respect to the relative risk of
a doubling of the serum creatinine concentration or
of end-stage renal disease. There was no significant dif-
ference among the three groups in the unadjusted risk
of death from any cause (Table 3).
 
Secondary, Cardiovascular Outcome
 
There were no significant differences among the
treatment groups in the secondary, cardiovascular out-
come (Table 3). The patients assigned to receive ir-
 
*Plus–minus values are means ±SD.
†The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡To convert values to micromoles per liter, multiply by 88.4.
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RBESARTAN
 
G
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(N=579)
A
 
MLODIPINE
 
 
G
 
ROUP
 
(N=567)
P
 
LACEBO
 
G
 
ROUP
 
(N=569)
P 
V
 
ALUE
 
Age — yr 59.3±7.1 59.1±7.9 58.3±8.2 0.63
Male sex — no. (%) 378 (65) 359 (63) 403 (71) 0.02
Race or ethnic group — no. (%) 0.33
Non-Hispanic white 438 (76) 389 (69) 415 (73)
Non-Hispanic black 63 (11) 87 (15) 78 (14)
Hispanic 28 (5) 29 (5) 26 (5)
Asian or Pacific Islander 24 (4) 34 (6) 27 (5)
Other 26 (4) 28 (5) 23 (4)
Body-mass index† 31.0±5.6 30.9±5.9 30.5±5.9 0.34
Blood pressure — mm Hg
Systolic 160±20 159±19 158±20 0.10
Diastolic 87±11 87±11 87±11 0.97
Insulin use at entry — no. (%) 329 (57) 327 (58) 335 (59) 0.78
History of cardiovascular disease — no. (%) 158 (27) 171 (30) 164 (29) 0.37
Retinopathy — no. (%) 401 (69) 362 (64) 380 (67) 0.19
Serum creatinine — mg/dl‡ 1.67±0.53 1.65±0.61 1.69±0.57 0.50
Urinary protein excretion — g/24 hr
Median 2.9 2.9 2.9 0.40
Interquartile range 1.6–5.4 1.6–5.2 1.8–5.2
Urinary albumin excretion — g/24 hr
Median 1.9 1.9 1.9 0.47
Interquartile range 1.0–3.8 1.0–3.5 1.1–3.5
Glycosylated hemoglobin — % 8.1±1.7 8.2±1.7 8.2±1.7 0.82
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besartan had a rate of congestive heart failure neces-
sitating hospitalization that was 23 percent lower
than that among the patients assigned to receive pla-
cebo. The patients assigned to receive amlodipine had
a rate of nonfatal myocardial infarction that was 41
percent lower than that among the patients assigned
to receive placebo.
 
Effect of Base-Line Covariates and Achieved Mean 
Arterial Pressure
 
Analyses were performed to ensure that the ob-
served differences in outcomes could not be explained
by imbalances in the distribution of the base-line co-
variates. The inclusion of these base-line covariates in
proportional-hazards analyses did not change the con-
clusions of the primary analyses.
The better renal outcomes in the irbesartan group
could not be explained by differences in the mean
arterial blood pressure during follow-up. The mean
arterial pressure in the irbesartan group was not sig-
nificantly different from that in the amlodipine group.
Furthermore, when we corrected for the mean arte-
rial pressure at each of the quarterly visits in a time-
dependent proportional-hazards analysis (Table 3), the
results were similar to those of the primary analysis.
 
Changes in Renal Function
 
The serum creatinine concentration, creatinine
clearance, and levels of urinary protein and albumin
excretion were similar in the three groups at base line
(Table 1). The serum creatinine concentration in-
creased 24 percent more slowly in the patients in the
irbesartan group than in those in the placebo group
(P=0.008) and 21 percent more slowly than in those
in the amlodipine group (P=0.02), despite the fact
that larger numbers of patients in the placebo and
amlodipine groups were excluded from further analy-
ses of the serum creatinine concentration when they
reached a renal end point. The serum creatinine slopes
in the placebo and amlodipine groups did not differ.
The mean (±SE) absolute rates of change in the se-
rum creatinine concentration were 0.45±0.04 mg per
deciliter per year in the irbesartan group, 0.57±0.04
mg per deciliter per year in the amlodipine group, and
0.59±0.04 mg per deciliter per year in the placebo
group. The mean rate of change in creatinine clear-
ance was ¡5.5±0.36 ml per minute per 1.73 m
 
2
 
 of
body-surface area per year in the irbesartan group,
¡6.8±0.37 ml per minute per 1.73 m
 
2
 
 per year in the
amlodipine group, and ¡6.5±0.37 ml per minute per
1.73 m
 
2
 
 per year in the placebo group. Proteinuria
was reduced on average by 33 percent (mean [±SD]
decrease in protein concentration, ¡1.1±1.7 g per
24 hours) in the irbesartan group, as compared with
6 percent (¡0.1±2.9 g per 24 hours) in the amlo-
dipine group and 10 percent (¡0.3±4.3 g per 24
hours) in the placebo group. These reductions were
maintained throughout the follow-up period.
 
*The numbers of patients with the composite end points are lower than the sums of those with
the various components because some patients reached more than one component.
†Patients who never received study medication were included in all analyses according to the in-
tention-to-treat principle.
‡Data are for patients lost to follow-up before reaching the primary outcome or the last scheduled
study visit.
§The duration of follow-up was calculated from the time of randomization to the occurrence of
the first primary outcome or the date of the last scheduled visit when data were censored.
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ROUP
 
(N=569)
A
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P
 
ATIENTS
 
(N=1715)
 
Primary composite outcome — 
no. (%)
189 (32.6) 233 (41.1) 222 (39.0) 644 (37.6)
Doubling of serum creatinine
concentration
98 (16.9) 144 (25.4) 135 (23.7) 377 (22.0)
End-stage renal disease 82 (14.2) 104 (18.3) 101 (17.8) 287 (16.7)
Death from any cause 87 (15.0) 83 (14.6) 93 (16.3) 263 (15.3)
Secondary composite outcome — 
no. (%)
138 (23.8) 128 (22.6) 144 (25.3) 410 (23.9)
Never received study medication 
— no. (%)†
2 (0.3) 8 (1.4) 6 (1.1) 16 (0.9)
Lost to follow-up — no. (%)‡ 5 (0.9) 2 (0.4) 4 (0.7) 11 (0.6)
Completed study without primary
outcome — no. (%)
385 (66.5) 332 (58.6) 343 (60.3) 1060 (61.8)
Mean duration of follow-up — 
days§
952 924 921 932
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Serious Adverse Events
 
One episode of an early increase in the serum cre-
atinine concentration suggestive of renal-artery ste-
nosis necessitated the stopping of the study medica-
tion. Hyperkalemia necessitating a discontinuation of
the study medication occurred in 11 of the patients
in the irbesartan group (1.9 percent), as compared
with 3 of those in the amlodipine group (0.5 per-
cent) and 2 of those in the placebo group (0.4 per-
cent, P=0.01 for both comparisons). Overall, 23.7
percent of the patients stopped receiving the study
medication without having reached the primary end
point and before their data were censored. The most
common reason for the discontinuation of the study
medication was the occurrence of a clinical cardio-
vascular event. These discontinuations were evenly dis-
tributed among the treatment groups. The number of
patients who had at least one serious adverse event (61
percent of the total cohort) reflected the advanced
stage of illness and the numerous risk factors in this
population, but the number did not differ significant-
ly among groups. The patients in the irbesartan group
had a significantly lower rate of adverse events per
1000 days of treatment than those in the placebo and
amlodipine groups (P=0.002).
 
DISCUSSION
 
The angiotensin-II–receptor antagonist irbesartan
was associated with better renal outcomes than the
other agents (amlodipine, placebo, and antihyperten-
sive agents) we used. A slowing of the rate of pro-
gression of nephropathy was reflected in a significant
increase in the time to a doubling of the serum cre-
atinine concentration, a measure that approximates a
halving of the glomerular filtration rate.
 
3
 
 A diminished
rate of progression of disease was not limited to the
patients in whom there was a doubling of the serum
creatinine concentration during follow-up. The mean
increase in the serum creatinine concentration and the
mean decrease in creatinine clearance were signifi-
cantly slower in the entire irbesartan group. The pa-
tients in the amlodipine group had worse renal out-
comes than those in the irbesartan group, although
there was equal control of blood pressure in the am-
lodipine group. When we adjusted for the disparity
in blood-pressure control between the irbesartan and
placebo groups, the extent of the estimated renal ben-
efit of irbesartan did not decrease significantly. We in-
terpret these results as demonstrating that irbesartan
was renoprotective in these patients with nephropa-
thy due to type 2 diabetes — an effect analogous to
 
Figure 1.
 
 Average Systolic, Mean Arterial, and Diastolic Blood Pressures at Randomization (0 Months)
and during Follow-up, According to Treatment Group.
The mean arterial pressure during follow-up was, on average, 3.3 mm Hg lower in the irbesartan and
amlodipine groups than in the placebo group.
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that of the ACE inhibitor captopril in patients with
nephropathy due to type 1 diabetes.3
The renoprotection provided by an angiotensin-
II–receptor antagonist derives solely from its restric-
tion of angiotensin activity. ACE inhibition may be less
specific and less complete. ACE is responsible for the
conversion of angiotensin I to angiotensin II, as well
as for the catalytic degradation of bradykinin.14 The
renoprotection associated with ACE inhibition has
been shown in rats to be the result of diminished gen-
eration of angiotensin and increased bradykinin con-
centrations.14 However, studies in humans have sup-
Figure 2. Cumulative Proportions of Patients with the Primary Composite End Point (Panel A) and Its
Components, a Doubling of the Base-Line Serum Creatinine Concentration (Panel B), End-Stage Renal
Disease (Panel C, facing page), and Death from Any Cause (Panel D, facing page).
The date of onset of end-stage renal disease could not be determined for one patient in the placebo
group and two patients in the amlodipine group. These three patients were excluded from the analyses
shown in Panels A and C.
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ported the notion that ACE inhibitors alter renal
hemodynamics primarily by diminishing the action
of angiotensin II.15-17 Thus, in both the renoprotec-
tion demonstrated by ACE inhibition in nephropathy
due to type 1 diabetes and that of angiotensin-receptor
blockers in nephropathy due to type 2 diabetes, the
important pharmacologic action appears to be the re-
striction of intrarenal angiotensin activity. The mech-
anism of renoprotection by agents that block the ac-
tion of angiotensin II may be complex, involving
hemodynamic factors that lower the intraglomerular
pressure,18 the beneficial effects of diminished pro-
teinuria,19 and decreased collagen formation20 that
may be related to decreased stimulation of transform-
ing growth factor b by angiotensin II.21
We cannot directly address the issue of whether the
effects of ACE inhibitors and angiotensin-receptor
blockers would be equivalent in the treatment of pa-
tients with nephropathy due to type 2 diabetes. It may
seem reasonable to assume that agents that primarily
reduce the generation or effect of angiotensin II
would have similar clinical results. However, it is im-
portant to caution that ACE inhibitors and angio-
tensin-receptor blockers are distinctly different class-
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es of drugs and that one cannot assume equivalence
between them. The pharmacologic activity of these
agents is complex. The effect of ACE inhibition on
renal hemodynamics could be limited by the non–
ACE-dependent generation of angiotensin II that has
been documented in patients in the hyperglycemic
state.17 It is noteworthy that the size-selective dysfunc-
tion of glomerular capillary permeability that charac-
terizes diabetic nephropathy is improved by ACE in-
hibition in patients with type 1 diabetes but not in
those with type 2 diabetes.4 The Ramipril Efficacy
in Nephropathy study failed to demonstrate renopro-
tection in patients with nephropathy due to type 2
diabetes who received ACE inhibitors.22 Patients who
received ramipril lost renal function at a significantly
faster rate than those assigned to other antihyperten-
sive agents.22 A subanalysis of patients in the United
Kingdom Prospective Diabetes Study concluded that
ACE inhibitors and b-adrenergic–blocking agents
were equally effective in preventing renal damage.8
Since b-adrenergic–blocking agents were commonly
used in our placebo group, one must note the con-
trast between the results of the United Kingdom Pro-
spective Diabetes Study and our results. The popula-
tion at risk in that study, however, was small, and the
comparison between ACE inhibitors and beta-block-
ers was not part of its primary design. One study of
the course of proteinuria in patients with microalbu-
minuria and type 2 diabetes indicated that ACE in-
hibition slowed the progression of renal disease.23 In
the light of conflicting information from previous
reports, we must limit our recommendations to those
that can be drawn from the results achieved with the
agent and dosage that we used in this study.
It should be noted that, although the differences
were not statistically significant, our irbesartan group
had lower rates of death from any cause and of the
secondary, cardiovascular end point than the placebo
group. These differences were slightly smaller than
the absolute differences in the risk of death from any
cause and the risk of other cardiovascular end points
that were reported in the Heart Outcomes Prevention
Evaluation Study.24 However, the statistically robust
result reported for that study was the product of its
statistical power for the detection of differences in
mortality with a total of 9297 patients, 3577 of whom
had diabetes. In our study, in which the sample was
much smaller, we found no statistically significant dif-
ferences in the rate of death from any cause or the
secondary, cardiovascular end point. Our study was
not designed to have adequate statistical power for
an analysis of these outcomes.
The amlodipine group had a significantly higher
rate of congestive heart failure than the placebo or
irbesartan group. This finding is in keeping with the
moderately increased risk of congestive heart failure
associated with calcium-channel blockers reported in
a recent meta-analysis that focused on hypertensive
*CI denotes confidence interval.
†The relative risks were adjusted for the mean arterial blood pressure during follow-up.
TABLE 3. RELATIVE RISKS OF OUTCOMES.*
OUTCOME
UNADJUSTED RELATIVE RISK
(95% CI)
P 
VALUE
ADJUSTED RELATIVE RISK
(95% CI)†
P
VALUE
Primary composite end point
Irbesartan vs. placebo 0.80 (0.66–0.97) 0.02 0.81 (0.67–0.99) 0.03
Amlodipine vs. placebo 1.04 (0.86–1.25) 0.69 1.07 (0.89–1.29) 0.47
Irbesartan vs. amlodipine 0.77 (0.63–0.93) 0.006 0.76 (0.63–0.92) 0.005
Doubling of serum creatinine
concentration
Irbesartan vs. placebo 0.67 (0.52–0.87) 0.003 0.71 (0.54–0.92) 0.009
Amlodipine vs. placebo 1.06 (0.84–1.35) 0.60 1.15 (0.91–1.46) 0.24
Irbesartan vs. amlodipine 0.63 (0.48–0.81) <0.001 0.61 (0.48–0.79) <0.001
End-stage renal disease
Irbesartan vs. placebo 0.77 (0.57–1.03) 0.07 0.83 (0.62–1.11) 0.19
Amlodipine vs. placebo 1.00 (0.76–1.32) 0.99 1.09 (0.82–1.43) 0.56
Irbesartan vs. amlodipine 0.77 (0.57–1.03) 0.07 0.76 (0.57–1.02) 0.06
Death from any cause
Irbesartan vs. placebo 0.92 (0.69–1.23) 0.57 0.94 (0.70–1.27) 0.69
Amlodipine vs. placebo 0.88 (0.66–1.19) 0.40 0.90 (0.66–1.21) 0.47
Irbesartan vs. amlodipine 1.04 (0.77–1.40) 0.80 1.05 (0.78–1.42) 0.75
Secondary, cardiovascular 
composite end point
Irbesartan vs. placebo 0.91 (0.72–1.14) 0.40 0.91 (0.72–1.14) 0.40
Amlodipine vs. placebo 0.88 (0.69–1.12) 0.29 0.88 (0.69–1.11) 0.27
Irbesartan vs. amlodipine 1.03 (0.81–1.31) 0.79 1.03 (0.81–1.32) 0.78
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patients without diabetes.25 Our report of a lower
risk of coronary events associated with calcium-chan-
nel–blocker therapy differs from the results of Hans-
son et al. in a larger trial in elderly hypertensive pa-
tients, which found no difference between therapy
with a calcium-channel blocker and therapy with an
ACE inhibitor with regard to the risk of coronary
events.26 It is possible that calcium-channel blockers
are more efficacious in lowering the rate of coronary
events in a population with diabetic nephropathy.
Our data reveal that irbesartan is renoprotective in
patients with type 2 diabetes and overt nephropathy
and that it significantly slows the progression of glo-
merulopathy. The beneficial effects of irbesartan were
accompanied by minimal drug-specific serious adverse
effects in our patients.
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